All AbMole products are for research use only, cannot be used for human consumption.
Onalespib (AT13387) is a non-geldanamycin inhibitor of HSP90, it inhibited the proliferation of imatinib-sensitive (GIST882, GIST-T1) and -resistant (GIST430, GIST48) cell lines, including those resistant to the geldanamycin analogue HSP90 inhibitor, 17-AAG. AT13387 showed a median EC(50) value of 41 nM and exhibited activity consistent with a cytotoxic effect in vitro. In vivo, antitumor activity of AT13387 was showed in both the imatinib-sensitive, GIST-PSW, xenograft model and a newly characterized imatinib-resistant, GIST430, xenograft model. AT13387 has shown activity against a wide array of tumor cell lines, including lung cancer cell lines. While AT13387 was rapidly cleared from blood, its retention in tumor xenografts was markedly extended, and it was efficacious in a range of xenograft models. A combination of AT13387 and imatinib treatment in the imatinib-resistant GIST430 model significantly enhanced tumor growth inhibition over either of the monotherapies.
| Cell Experiment | |
|---|---|
| Cell lines | HCT116, A549, MCF-7, U266, PANC1, Huh-7, DU145, MES-SA, SKOV3, HL60, A375 and TFK-1 cells line |
| Preparation method | Proliferation assays. Cells were seeded into 96-well plates before the addition of compound in 0.1% (v/v) DMSO. GI50 were determined using a 10-point dose response curve for three cell doubling times. After compound incubation 10% (v/v), Alamar blue (Biosource International, Camarillo, CA, USA) was added, and cells were incubated for a further 4 h. Fluorescence was read at λex = 535 nm and λem = 590 nm. |
| Concentrations | 0~1 μ M |
| Incubation time | 48 or 72 h |
| Animal Experiment | |
|---|---|
| Animal models | Athymic mice bearing NCI-H1975 xenografts |
| Formulation | 17.5% (w/v) hydroxypropyl-β-cyclodextrin |
| Dosages | 70 mg/kg on days 1, 4, 8, 12 and 16; 55 mg/kg on days 1, 4, 8, 12 and 16; or 90 mg/kg on days 1, 8 and 16. |
| Administration | intraperitoneally |
| Molecular Weight | 409.52 |
| Formula | C24H31N3O3 |
| CAS Number | 912999-49-6 |
| Solubility (25°C) | DMSO 25 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related HSP Products |
|---|
| BIIB021
BIIB021 (CNF2024) is an orally available synthetic non-ansamycin Hsp90 inhibitor with ki value of 1.7nM. |
| CUDC-305
CUDC-305 is a heat shock protein 90 (HSP90) inhibitor of the novel imidazopyridine class, with IC50 values of 100 and 103 nM for HSP90α and HSP90β, respectively. |
| Ganetespib
Ganetespib (STA-9090) is a potent synthetic small molecule inhibitor of Hsp90 with potential antineoplastic activity. |
| Luminespib (AUY922)
Luminespib (AUY922) is a small molecule Heat Shock Protein 90 (HSP90) inhibitor with IC50 values of 13 and 21 nM for HSP90α and HSP90β respectively. |
| NVP-HSP990
NVP-HSP990 is an orally bioavailable inhibitor of human heat-shock protein 90 (Hsp90) with IC50 values of 0.6, 0.8, and 8.5 nM for Hsp90α, Hsp90β, and Grp94, respectively. NVP-HSP990 has potential antineoplastic activity. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
